Drug And Alcohol Treatment Plans
Intercept Pharmaceuticals to collaborate with the NIDDK study Obeticholic acid (INT-747) in non-alcoholic … Drug Interdiction, Inc., a clinical stage biopharmaceutical company dedicated to developing new therapies for chronic fibrotic and metabolic diseases, announced today the signing of a cooperative agreement for research and development with the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health to conduct a double blind, multicenter, study to …
Miramar Drug Rehab Center- Dual Diagnosis Treatment in a Drug and Alcohol Rehab
